Mark A. Green, PhD
Professor of Radiology & Imaging Sciences
Professor Green serves as the Director of Radiopharmaceutical Sciences for the Indiana Institute for Biomedical Imaging Sciences (IIBIS) in the Department of Radiology and Imaging Sciences.
To support basic and clinical research investigations employing positron emission tomography (PET), the Radiology's PET Radiochemistry Core Facility operates an 11-MeV cyclotron for the routine production of short-lived PET radiopharmaceuticals. Associated research infrastructure includes 19 Comecer hot cells; multiple automated radiochemical synthesis systems for preparation of oxygen-15, nitrogen-13, carbon-11, and fluorine-18 radiopharmaceuticals; and a pneumatic tube system for rapid radiopharmaceutical transport to our multiple PET camera sites.
Professor Green’s research focus is the design, synthesis, evaluation, and validation of new radiopharmaceutical agents. The practice of nuclear medicine is based on imaging the internal distribution and pharmacokinetics of such radioactive drugs, drugs that selectively and specifically probe clinically relevant aspects of regional tissue function (normal vs. pathophysiology). Radiochemically, his research is primarily exploring applications for short-lived metallic radionuclides (e.g., copper-62, copper-64, gallium-68); nuclides selected for investigation because they offer unique and/or attractive nuclear and chemical properties. Current research interests include: development of tracers for the study of regional tissue perfusion (cerebral, myocardial, renal, and tumor blood flow); strategies for selective radiotracer targeting to neoplastic tissue; and general biomedical applications of radiotracer methods.
Imaging Regional Perfusion, Including Tumor Perfusion, with Whole-Body Positron Emission Tomography:
Whole-body PET/CT evaluation of tumor perfusion using generator-based 62Cu-ethylglyoxal bis(thiosemicarbazonato)copper(II): validation by direct comparison to 15O-water in metastatic renal cell carcinoma.
Fletcher JW, Logan TF, Eitel JA, Mathias CJ, Ng Y, Lacy JL, Hutchins GD, Green MA.
J Nucl Med. 2015 Jan;56(1):56-62. doi: 10.2967/jnumed.114.148106. Epub 2014 Dec 18.
- PMID: 25525184
Prostate Cancer Imaging with Positron Emission Tomography and PSMA-Targeted Radiopharmaceuticals:
Green MA, Eitel JA, Fletcher JW, Mathias CJ, Tann MA, Gardner T, Koch MO, Territo W, Polson H, Hutchins GD.
Nucl Med Biol. 2017 Mar;46:32-35. doi: 10.1016/j.nucmedbio.2016.11.002. Epub 2016 Nov 4.
- PMID: 28012435
Radiology & Imaging Sciences
R2 E124 RADY
Development and Validation of Radiotracer Methods for Application in Biomedical Research and Clinical Care
Agents for imaging with positron emission tomography (PET).
Biomedical applications of radiometals in diagnosis anf therapy.
Research Scope Includes:
• Benchtop synthetic chemistry (inorganic and organic).
• Radiochemical synthesis and characterization.
• Radiopharmaceutical screening and evaluation in biological models.
• Formulations chemistry.
• Translation to human imaging studies for assessment of performance/utility.
Commonly employed radionuclides: Cu-62, Cu-64, Ga-68, C-11, F-18, and O-15.
Sigma Xi, The Scientific Research Society
Society of Nuclear Medicine and Molecular Imaging
Society of Radiopharmaceutical Sciences